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doi:10.1Background: Surgery for congenital heart disease initiates a complex inflammatory response that can influence
the postoperative course. However, broad integration of the cytokine and proteolytic cascades (matrix metallo-
proteinases: MMPs), which may contribute to postoperative outcomes, has not been performed.
Methods and Results: Using a low-volume (50–60 mL), high-sensitivity, multiplex approach, we serially
measured a panel of cytokines (interleukins 2, 4, 6, 8, and 10, tumor necrosis factor alpha, interleukin 1b,
and granulocyte-macrophage colony stimulating factor) and matrix metalloproteinases (matrix metalloprotei-
nases 2, 3, 7, 8, 9, 12, and 13) in patients (n ¼ 9) preoperatively and after repair of ventricular septal defect.
Results were correlated with outcomes such as inotropic requirement, oxygenation, and fluid balance. Serial
changes in perioperative plasma levels of the cytokines and matrix metalloproteinases exhibited distinct tem-
poral profiles. Plasma levels of interleukins 2, 8, and 10 and matrix metalloproteinase 9 peaked within 4
hours, whereas levels of matrix metalloproteinase 3 and 8 remained elevated at 24 and 48 hours after cross-
clamp removal. Area-under-the-curve analysis of early cytokine levels were associated with major clinical
variables, including inverse correlations between early interleukin 10 levels and cumulative inotrope require-
ment at 48 hours (r:0.85; P< .005) and late matrix metalloproteinase 7 levels and cumulative fluid balance
(r:0.90; P< .001).
Conclusions: The unique findings of this study were that serial profiling a large array of cytokines and proteolytic
enzymes after surgery for congenital heart disease can provide insight into relationships between changes in bio-
active molecules to early postoperative outcomes. Specific patterns of cytokine and matrix metalloproteinase re-
lease may hold significance as biomarkers for predicting and managing the postoperative course after surgery for
congenital heart disease. (J Thorac Cardiovasc Surg 2010;140:1257-65)The importance of post–cardiopulmonary bypass (CPB)
inflammation in pediatric cardiac surgery is reflected in the
many interventions directed at its reduction. Steroid admin-
istration, modification of pump circuit surfaces by heparin
bonding, ultrafiltration strategies, leukocyte trapping filters,
reduced post-CPB oxygen exposure, and monoclonal anti-
body administration have all been described to modify
features of the post-CPB inflammatory response in new-
borns, infants, and children.1 Despite this, a survey of 36
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The Journal of Thoracic and Carinflammatory strategy achieved the level of standard practice
in the pediatric CPB population, reflecting absence of con-
vincing data to guide therapies. CPB engenders inflamma-
tion through multiple mechanisms, including direct tissue
injury, myocardial ischemia/reperfusion, neutrophil/platelet
activation from the CPB circuit, and lipopolysaccharide
exposure.2 The molecular events of inflammation include
synthesis and release of cytokines, which in turn induce com-
plex and context-dependent cellular and molecular events,
including release of matrix metalloproteinases (MMPs).3
The characteristic pleiotropy, redundancy, and complexity
of the inflammatory response have complicated efforts to de-
fine this process in infants owing to the number of inflamma-
tory biomarkers to consider in relation to relative volume of
blood available for sampling. This study was performed to
address this issue through the use of high-sensitivity multi-
plex assays to allow serial measurement of cytokine and
MMP levels from repeated small-volume blood sampling
in a population of infants undergoing repair of ventricular
septal defect (VSD). This study provided the first opportu-
nity to perform a comprehensive cytokine/MMP profile
and begin to identify potential relationships between the
inflammatory response and clinical outcomes.diovascular Surgery c Volume 140, Number 6 1257
Abbreviations and Acronyms
AUC ¼ area under the curve
BSA ¼ body surface area
CPB ¼ cardiopulmonary bypass
GM-CSF ¼ granulocyte-macrophage colony
stimulating factor
IL ¼ interleukin
INF-g ¼ interferon gamma
MMP ¼ matrix metalloproteinase
Th ¼ T-helper
TNFa ¼ tumor necrosis factor alpha
VSD ¼ ventricular septal defect
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Patients
This study was approved by the Medical University of South Carolina
Institutional Review Board (HR 16017 and HR 17161). Entry criteria for
the VSD group were planned complete surgical repair of the anatomic de-
fect and age from 1 to 9 months. Exclusion criteria were recognized chro-
mosomal anomalies, prior intracardiac surgery, or complex heart disease.
Enrollment was from January 2006 through June 2007, and the cardiac
surgeons remained constant during this interval (F.A.C., S.M.B.). The
conduct of CPB was performed in identical fashion and aprotinin was
used in all cases. Standard nonpulsatile CPB was used, and the circuit
was primed with electrolyte solution (PlasmaLyte A; Baxter Healthcare
Corporation, Deerfield, Ill) and 1 unit of fresh-frozen plasma. Banked,
packed red blood cells were added to achieve a hematocrit value of ap-
proximately 28% to 30% during CPB. No steroids were administered pre-
operatively or in the CPB prime. Moderate (25C–28C) hypothermia was
used, and myocardial preservation was obtained with cold blood cardio-
plegia at 20-minutes intervals. The pH-stat regimen was used during cool-
ing and alpha-stat for rewarming. Modified ultrafiltration was performed
after separation from CPB. Protamine was given at a 0.6:1 protamine/hep-
arin ratio. Blood product transfusions after CPB were administered as nec-
essary to achieve satisfactory hemostasis and a target hematocrit value of
more than 30%. Standard transatrial closure of the VSD was used in all
patients. The aprotinin dose consisted of both an intravenous and pump
prime load of 240 mg/m2 body surface area (BSA) (1.7 3 106 kIU/m2
BSA) and a continuous infusion at 56 mg/m2 BSA/h (4 3 105 kIU/m2
BSA/h) until the completion of the primary procedure. For the purposes
of providing a referent control range, a group of 10 infants were recruited
from patients undergoing ambulatory noncardiac surgery. In this group,
a 1-time venous blood collection (1 mL) was performed at the time of
intravenous cannulation.
Clinical Data Collection
Clinical characteristics such as age, weight, and BSA, as well as z-score
for weight, were recorded. Data recorded or calculated during the 48-hour
study period included CPB and crossclamp times, arterial blood gases,
blood counts, and arterial–alveolar oxygen gradients at 4 hours. Inotrope
score was calculated as dopamine ([mg $ kg1 $ min1] 3 h)þepinephrine
([mg $ kg1 $ min1] 3 h 3 100) þ milrinone ([mg $ kg1 $
min1] 3 h 3 10). Fluid balance was calculated as total fluid administered
(all sources) minus total fluid out (all sources). Inotrope score, fluid
balance, and near-infrared spectroscopy were analyzed as cumulative
values from time of arrival in the postoperative care unit. In addition,
blood product use was recorded during the operative and perioperative
periods.1258 The Journal of Thoracic and Cardiovascular SurBlood Collection and Processing
Baseline blood (1 mL) was collected in the operating room before the in-
cision into a chilled ethylenediaminetetraacetic acid tube. Plasma was iso-
lated by centrifugation, decanted into aliquots, and stored at70C until
processed for immunoassays. Subsequent 1-mL samples were obtained after
modified ultrafiltration and 4, 12, 24, and 48 hours after crossclamp removal
and processed identically. Crossclamp removal (onset of myocardial reper-
fusion injury) was the reference time 0 for postoperative measurements.
Quantitative Measures of Cytokines and MMPs
Plasma levels of cytokines and MMPs were determined by multiplex
suspension array using calibrated and validated combinatorial immunoas-
says (R&D Systems, Minneapolis, Minn). For cytokines, measurements
were made from undiluted plasma. For MMP analysis, plasma was diluted
1:10 forMMP-3, -7, -8, -12, and -13 and 1:100 for MMP-2 and -9. The iden-
tification and quantification of the analyte/bead complexes were determined
by flow cytometry with dual excitation lasers (the excitation and emission
wavelengths are 532 nm and 575 nm, respectively; Bio-Plex SuspensionAr-
rayWorkstation; Bio-Rad, Hercules, Calif). Each analyte concentration was
calculated from an analyte-specific 5-parameter logistic calibration equation
(Bio-Plex Manager Software 4.1.1). Average sensitivities for cytokines
were 0.3 pg/mL and 5 pg/mL for MMP/tissue inhibitors of metalloprotei-
nases. The cytokine and MMP multiplex assays have less than 0.5%
cross-reactivity and interference with the other measured analytes. Plasma
values were corrected for hemodilution using simultaneously obtained
hematocrit values.
Data Analysis
Patient demographics and preoperative values for plasma levels of cyto-
kines and MMPs were compared between the control and VSD groups by
the Kruskal–Wallis test of medians. Comparisons were withheld if the ana-
lyte failed to be detectable in at least 25% of the samples for each group. For
postoperative analysis, 2 area-under-the-curve (AUC) values were derived
from the time course of expression for each analyte. Early AUC was deter-
mined as the dose 3 time product (summation of the areas of individual
trapezoids) for each analyte from baseline to the 4-hour post-crossclamp
time point. Late AUC was computed in the same fashion for the 4- to
48-hour interval. For AUC determinations, an undetectable level was set
at 0. Correlations between AUCs for each cytokine/MMP and clinical out-
comes, as well as between early and late AUCs, were examined by the
Spearman correlation analysis. Statistical tests were performed using
the Stata software package (Stata Intercooled, v8.0) or SAS (SAS, Inc,
Cary, NC).RESULTS
Demographics
The patients undergoing VSD closure were 4.3  0.5
months old, whereas the referent normal control subjects
were older (7.8  1.3 months; P< .05), but nevertheless
could be used for the purposes of generating a referent nor-
mal range for the cytokine and MMP assays. The male/fe-
male ratio in the VSD group was 4:5 and similar in the
referent control group (5:5). Preoperative white blood
counts, platelet counts, and serum measurements of renal
function (electrolytes, blood urea nitrogen, and creatinine,
not shown) were all within the normal range for the VSD pa-
tients. Crossclamp time, CPB time, intubation times, cumu-
lative introtrope score, fluid balance, near infrared
spectroscopy, and blood product use for the VSD patients
are summarized in Table 1.gery c December 2010
TABLE 1. Intraoperative and perioperative characteristics in
subjects with a VSD
Crossclamp time (min) 57.2  5.0
CPB time (min) 95.7  7.4
Intubation time (h) 36.2  3.3
Inotrope score (mg $ kg1 $ min1 3 h) 126  34
Fluid balance (mL) 5.3  12.5
NIRS (%) 66.3  2.3
Blood product use
Packed red blood cells (units) 1 (1)
Fresh frozen plasma (units) 0 (1)
Cryoprecipitate (units) 0 (0)
Platelets (units) 1 (0)
Sample size (n) 9
Times, inotrope score, and fluid balance are presented as mean SEM. Blood product
use is presented as median (interquartile range). VSD, Ventricular septal defect; CPB,
cardiopulmonary bypass; NIRS, near-infrared spectroscopy, average of values
recorded in intensive care unit.
TABLE 2. Baseline plasma cytokine and MMP levels in referent
control subjects and subjects with VSD
Control IQR VSD IQR
P
value
TNF-a (pg/mL) 4.25 (10) 3.12–5.62 2.87 (9) 2.38–3.89 .19
IL-2 (pg/mL) 4.5 (10) 3.07–4.68 1.76 (8) 1.09–2.64 .03
IL-6 (pg/mL) 0.57 (10) 0.49–0.96 0.83 (9) 0.49–2.66 .59
IL-8 (pg/mL) 2.68 (10) 1.78–5.24 4.98 (9) 3.94–5.17 .33
IL-10 (pg/mL) 0.81 (6) 0.00–1.44 0.00 (4) 0.00–1.03 .63
INFg (pg/mL) 1.11 (9) 0.33–1.42 0.33 (8) 0.17–0.62 .13
GM - CSF (pg/mL) 0.30 (5) 0.00–1.00 0.00 (3) 0.00–0.39 .23
MMP-2 (ng/mL) 364 (10) 328–471 401 (9) 293–536 .74
MMP-3 (pg/mL) 1346 (10) 821–2079 1080 (9) 720–1816 .68
MMP-7 (pg/mL) 2615 (10) 2320–3151 2275 (9) 1355–2514 .29
MMP-8 (pg/mL) 1033 (10) 810–1941 1722 (9) 1664–2112 .41
MMP-9 (ng/mL) 26 (10) 21–48 39 (9) 30–44 .37
MMP-13 (pg/mL) (1) 85 (5) 0–318 .03)
Values are presented as median (number of samples with detectable levels). VSD,Ven-
tricular septal defect; IQR, interquartile range; TNF-a, tumor necrosis factor alpha; IL,
interleukins; INFg, interferon gamma; GM-CSF, granulocyte-macrophage colony
stimulating factor; MMP, matrix metalloproteinase. P values from nonparametric
2-sample Kruskal–Wallis test of medians except for the final value ()), which is
Pearson c2.
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Baseline levels for tumor necrosis factor alpha (TNF-a),
the interleukins (ILs), interferon gamma (INF-g), and
granulocyte-macrophage colony stimulating factor (GM-
CSF) for the referent control and VSD groups are summa-
rized in Table 2. IL-1b, IL-10, andGM-CSFwere detectable,
but to a variable degree, in each group. Other cytokines
assayed (TNF-a, IFN-g, IL-2, IL-6, and IL-8) were detect-
able at baseline in 90% or more samples. Plasma levels of
IL-2 were lower in the VSD group than in referent control
values.
Baseline MMP plasma levels for the referent control and
VSD groups are shown in Table 2. MMP-12 was not detect-
able in either group and therefore was excluded from further
analysis. Plasma MMP levels at baseline were similar be-
tween the groups, with one notable exception in which
MMP-13 was detectable in 5 of 9 VSD patients but 1 of
10 controls (P ¼ .033, Pearson c2).Postoperative Cytokine and MMP Measurements
Using the multiplex array analysis, we constructed a full
temporal profile for cytokines (Figures 1 and 2) and for
MMPs (Figure 3). These temporal profiles were examined
with respect to referent normal control ranges, baseline
values, as well as in reference to the intraoperative event—
crossclamp release and completion of modified ultrafiltra-
tion. In general, with the exception of IFN and IL-2,
cytokine values increased in the early perioperative period.
The cytokine IL-6 increased to the greatest relative degree,
and IL-10 levels peaked the earliest. An individual response
plot for IL-6 as a function of baseline values is shown in
Figure 4. All other cytokines with significant elevations
peaked at 4 hours after crossclamp, with the exception of
IL-1b, which was detected in only 3 of 9 subjects at the
end of modified filtration, became more regularly detectable
at 4, 12, and 24 hours, and returned to undetectable in 7 of 8The Journal of Thoracic and Carsamples at 48 hours. No cytokine remained significantly
elevated over baseline levels at 48 hours.
With respect to the full array of MMPs, a dynamic and di-
verse portfolio of changes occurred in the early perioperative
period. Plasma levels of MMP-8 and MMP-9 increased in
the early post-CPB period, whereas MMP-2 and MMP-7
levels actually fell from baseline values. Plasma MMP-3
levels increased in the later post-CPB time points and did
not return to baseline values. All other MMPs changed sig-
nificantly from baseline at some time point. A representative
individual response plot for MMP-9 is presented in Figure 4.
PlasmaMMP-2 levels were significantly lower than baseline
levels in the early postoperative period but returned to base-
line levels at 48 hours.Postoperative Inflammatory Markers and Clinical
Outcomes
We examined the hypothesis that early or late cytokine/
MMPAUCswere linked to specific operative events or post-
operative outcomes such as crossclamp time, inotrope score,
net fluid balance, and blood product use. Early IL-10 AUC
was negatively correlated with cumulative inotrope require-
ment at 48 hours (r:0.85, P< .005). Early GM-CSF was
negatively correlated with crossclamp time (r: 0.85,
P< .005). The late MMP-8 AUC was negatively correlated
with crossclamp time (r:0.87, P<.005), as was late MMP-
9AUC (r:0.73,P<.03). LateMMP-7AUCwas negatively
correlated with cumulative fluid balance (r:0.9, P< .001).
The early MMP-2 AUC, as well as the late MMP-2 AUC,
was negatively associated with packed red blood cell use
(r ¼0.88, r ¼0.68, respectively, both P< .05).diovascular Surgery c Volume 140, Number 6 1259
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FIGURE 1. Time course for perioperative and postoperative plasma levels (SEM) of IL-6, IL-10, IL-2, and interferon gamma (INF-g) in infants under-
going repair of a ventricular septal defect (VSD). The T-helper 1 cytokines (IL-2 and IFN-g) never increase above baseline values. The shaded bars indicate
the range of mean baseline values SEM. Baseline values were obtained before the incision, XC samples were obtained after modified ultrafiltration, and the
other time points are measured from crossclamp removal. Note the variation in the Y-axis scale (all in pg/mL). #P<.05 vs baseline values,þP<.05 versus
values after modified ultrafiltration (XC values). IL, Interleukin.
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DDISCUSSION
Although CPB is essential for the conduct of a large num-
ber of cardiac surgical procedures, the post-CPB period is as-
sociated with a heightened inflammatory response as
demonstrated by cellular and noncellular indices of immune
activation.2,4-7 This inflammatory response is characterized
by the release of cytokines and, through binding to cognate
receptors, results in a number of cellular and extracellular
events such as cell death and induction of proteolytic
pathways. For example, cytokine activation is an upstream
pathway for the induction of proteolytic enzymes such as
the MMPs.3,5 Increased MMP induction in and of itself
can lead to significant changes in tissue structure and
function and has been demonstrated to play a contributory
role in a number of acute and chronic cardiovascular
disease states.3,8-12 Specifically, MMP induction can
directly affect wound healing, alter vascular permeability
and reactivity, and contribute to multiorgan dysfunction.8-12
Thus, cytokine activation and MMP induction would hold
particular relevance in the context of surgical repair
of congenital defects requiring CPB. Past studies have1260 The Journal of Thoracic and Cardiovascular Surfocused on a small number of cytokines, at a limited
number of time points after pediatric heart surgery
requiring CPB.2,4,7 However, full temporal cytokine and
MMP plasma profiles have not been simultaneously
performed in this patient population previously, and these
values related to perioperative outcomes. The unique
results of the present study demonstrated that inflammatory
cytokine induction occurs after VSD repair in children,
which is temporally related to the emergence of a specific
MMP profile. Moreover, this specific cytokine and MMP
profile was associated with ischemic time (crossclamp
time), inotropic requirements, postoperative fluid balance,
and blood product use. The present study provided the
clinical proof of concept that profiling a large array of
relevant bioactive molecules reveals a distinctive signature
in infants undergoing surgery for congenital heart
disease, which may hold relevance with respect to the
underpinning pathophysiologic events that occur in the
early postoperative period as well as potential adjunctive
use as biomarkers for prognosis and perioperative
management.gery c December 2010
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FIGURE 2. Time course for perioperative and postoperative plasma levels of the cytokines TNF-a, GM-CSF, IL-8, and IL-1b in infants undergoing repair of
a ventricular septal defect (VSD). TNF-a, GM-CSF, and IL-8 have similar time courses, peaking at 4 hours and declining rapidly. IL-1b increases from es-
sentially undetectable levels to a peak at 24 hours before returning to generally undetectable levels at 48 hours. The shaded bars indicate the range of mean
baseline values SEM. Baseline values were obtained before the incision, XC samples were obtained after modified ultrafiltration, and the other time points
are measured from crossclamp removal. Note the variation in the Y-axis scale (all in pg/mL). #P< .05 versus baseline values,þP< .05 versus values after
modified ultrafiltration (XC values). TNF-a, Tumor necrosis factor alpha; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin.
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Repair
Past studies that have examined cytokine release, particu-
larly that in surgery for congenital heart disease, have been
limited by either cytokine type or time points after
CPB.2,4,7,13 One likely rate-limiting step in these past studies
is that cytokines were performed using a high sample volume
immunoassay approach, and therefore blood sample vol-
umes would be problematic. In the present study, a validated
high-sensitivity approach was used that provided the ability
to measure multiple analytes using a single, small-volume
plasma sample.14 Through this approach, multiple cytokines
could be measured simultaneously, which thereby reduced
intrinsic assay variability and allowed for sequential analy-
sis. Moreover, these values were placed in context with ref-
erent normal values obtained from children without
cardiovascular disease. The outcomes from this analysis
demonstrated that a robust increase in certain cytokines
occurred immediately after CPB, which included IL-2, IL-
6, IL-8, IL-10, and IL-1b, TNF-a, and GM-CSF. Although
the peak levels of IL-6 and IL-10 that were observed in the
present study are consistent with those reported previouslyThe Journal of Thoracic and Carafter surgery for congenital heart disease,4,7 the ability to
perform a full cytokine array across time provided some
unique insights. First, the pattern of cytokines released is
likely reflective of the underlying biology of the immune
response in these VSD patients. Specifically, a polarization
of cytokine expression occurs early in development, with
subsets of lymphocytes such as T-helper 1 cells (Th1)
expressing IL-2, TNF-a, and INF, whereas T-helper 2
(Th2) cells do not.15 There were 3 relevant observations
from the present study that would suggest that a Th2 polari-
zation occurred in VSD patients. First, the Th1 cytokine IL-2
values were lower at baseline in VSD infants compared with
referent normal values. Second, perioperative values of the
Th2 cytokines IL-10 and IL-6 were significantly increased.
Third, the Th1 cytokines IFN-g and IL-2 were reduced in
the perioperative period. This pattern of mild Th2 polariza-
tion has been observed previously in newborns.15 This spe-
cific cytokine profile remained elevated for a much greater
period after CPB than in adults undergoing cardiac sur-
gery.16 These findings underscore the fundamental differ-
ences in the immune response in newborns undergoing
cardiac surgery and that the subsequent inflammatorydiovascular Surgery c Volume 140, Number 6 1261
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FIGURE 3. Time course for perioperative and postoperative plasma levels of MMP-2, MMP-3, MMP-7, MMP-8, and MMP-9 in infants undergoing repair
of a ventricular septal defect (VSD). MMP-2 and MMP-7 values drop below baseline, whereas MMP-8 and MMP-9 values increase with dissimilar time
courses. MMP-3 increases steadily through the period from 4 to 48 hours postoperatively. The shaded bars indicate the range of mean baseline values 
SEM. Baseline values were obtained before the incision, XC samples were obtained after modified ultrafiltration, and the other time points are measured
from crossclamp removal. Note the variation in the Y-axis scale (all in pg/mL). #P< .05 versus baseline values,þP< .05 versus values after modified ul-
trafiltration (XC values). MMP, Matrix metalloproteinase.
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Dresponse may be much different from that which would be
anticipated in older children or adults. Thus, profiling the
unique cytokine signature that occurs in the perioperative pe-
riod after pediatric cardiac surgery may hold relevance when
developing specific anti-inflammatory strategies for this par-
ticularly vulnerable patient population.1
Both IL-6 and IL-8 are potent proinflammatory cytokines
that are chemoattractants for inflammatory cells2,13 and
remained substantially elevated up to 48 hours after CPB.1262 The Journal of Thoracic and Cardiovascular SurAlthough the present study was not designed or powered
to develop prediction models for cytokine profiles and
postoperative outcomes, some relative associations could
be made. First, heightened release of proinflammatory
cytokines such as IL-6 and IL-8 after surgery for congenital
heart disease has been associated previously with pulmonary
dysfunction, capillary leak syndrome, and oxidative stress
resulting in changes in endothelial and vascular reactivity
and function.2,13 Second, IL-10, which can be consideredgery c December 2010
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FIGURE 4. Top, Individual response plots for plasma IL-6 levels in the
patients undergoing repair of a ventricular septal defect (VSD) at baseline
and after crossclamp removal (XC) and modified ultrafiltration. Whereas the
relative magnitude varied between patients, IL-6 levels increased at this early
post-CPB time point. Bottom, Individual response plots for plasma MMP-9
levels in the VSD patients at baseline and at XC. Overall, a robust increase
in plasmaMMP-9 levels occurred at this early post-CPB time point. The darker
solid lines indicate the mean baseline and XC values SEM. #P<.05 versus
baseline values. IL, Interleukin; MMP, matrix metalloproteinase.
McQuinn et al Congenital Heart Disease
C
H
Dan anti-inflammatory molecule,17 increased early in the post-
CPB period but fell toward baseline values at later time
points. Indeed, the present study demonstrated that the rela-
tive magnitude of the early release of IL-10 was associated
with a decreased inotrope score, suggestive of the potentially
protective effects of this specific cytokine. Third, the release
of IL-1b into the circulation is due to cleavage by caspase-
1,18 suggestive of a gradual increase and rapid shutdown
of caspase-1–dependent inflammatory pathways in infants
after VSD repair. Finally, robust burst of TNF-a release oc-
curred in the VSD patients after CPB, and the myocardium
has been shown to be a potent source of this pleotropic cy-
tokine.19 In the present study, the relative magnitude of
the TNF-a response in comparison to the IL-6 response after
CPB is characteristic of neonatal monocytes.20 One unique
bioactive molecule measured in the present study wasThe Journal of Thoracic and CarGM-CSF, which increased transiently in the early perioper-
ative period and was inversely correlated to crossclamp time.
GM-CSF plays a fundamental role in the maturation of the
monocyte/macrophage lineage, and transfusion of GM-
CSF has been used for neonates with neutropenia and sep-
sis.21 However, mechanistic and clinical relationships of
changes in GM-CSF in pediatric patients after cardiac sur-
gery will require a much greater sample size and longer
follow-up periods.
Temporal Profile of MMP Release After VSD Repair
A common downstream biological event after cytokine re-
lease is the induction and activation of MMPs. Indeed, past
studies in adults after cardiac surgery have clearly demon-
strated a significant increase in certain MMP types after
CPB.5,6 Specifically, past studies in adults have identified
a robust increase of plasma MMP-8 and -9 after CPB.5,6
The present study is the first to examine and compare large
portfolios of MMPs in referent normal pediatric subjects,
as well as in patients after surgery for congenital heart
disease. This approach yielded several important
observations. First, detectable plasma MMP-13 levels oc-
curred with greater frequency in VSD patients compared
with referent normal subjects. MMP-13 is elevated in the
myocardium of patients with left ventricular failure,22 and
the presence or absence of plasma MMP-13 may hold rele-
vance as to the etiology of the cardiovascular pathophysio-
logic process that underlies adult patients with left
ventricular failure. Second, not all MMP types were uni-
formly increased in the perioperative period, and the tempo-
ral pattern of release appeared to be also different between
MMP types. For example, relative MMP-2 and MMP-7
levels actually decreased after CPB. This would imply that
there are different regulatory pathways for specific MMP
types, which would be operative in children undergoing car-
diac surgery. Whether the relative reduction in MMP-2
levels observed in the early perioperative period in the pres-
ent study was due to a relatively low capacity to upregulate
this particular MMP with respect to transcriptional activity,
relatively low stores of preformed pro-MMP-2, increased
consumption and degradation of this MMP type before spill-
over into the circulation, or a combination of these factors re-
mains to be established. Potential cardiac sources of MMP-7
include macrophages and cardiomyocytes.3,19 Thus, the
relative reduction of this specific MMP type may be
indicative of the relative immaturity of the immune system
and myocardium. Although the mechanisms that underlie
the relative reduction inMMP-2 andMMP-7 remain to be es-
tablished, the present study identified that MMP-2 levels
were negatively correlated with packed red blood cell use
andMMP-7 levels were negatively correlated with perioper-
ative fluid retention. These observations, albeit associative,
underscore the functional diversity of MMPs, whereby
some MMP types may play a predominant pathologic rolediovascular Surgery c Volume 140, Number 6 1263
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logical processes.
MMP types that are most associated with an inflamma-
tory process, such as MMP-8 and MMP-9, increased dra-
matically in the early post-CPB time points and were
temporally related to the release of proinflammatory cyto-
kines such as IL-6, IL-8, and TNF-a. Thus, although only
associative, this would suggest that the early and robust in-
crease in these cytokines would facilitate the egress of neu-
trophils and subsequent release of MMP-8 and MMP-9.
Indeed, the primary source of MMP-8 is neutrophils and
has been consequently termed neutrophil collagenase. The
increased levels of these specific MMP types would likely
have significant consequences on tissue structure and func-
tion in the early post-CPB period. For example, changes in
MMP levels can directly affect the wound healing response,
and changes in levels of MMP-8 can directly affect the time
course of wound healing.2,10,23 Indeed, levels of MMP-3
and MMP-9, both of which changed in the present study,
have been associated with wound healing after burn injury
in children.12 Inasmuch as the relative magnitude of MMP
release would likely play a contributory factor in endothe-
lium–matrix interaction and stability, then it is likely that
this proteolytic system contributes to the loss of capillary in-
tegrity that can often occur after surgery for congenital heart
disease.2,10,23
LIMITATIONS AND CONCLUSIONS
Although the present study provided the proof of principle
that a large portfolio of cytokines and MMPs can be serially
examined in pediatric patients undergoing cardiac surgery,
several limitations must be recognized. First, this study was
performed in a small number of patients and therefore robust
relationships between a specific cytokine/MMPprofile to crit-
ical outcomes, such as major morbidity and mortality end
points, could not be established. Second, the study was per-
formed in the context of a surgical repair of a relatively simple
congenitalmalformation—VSD; therefore, extension of these
findings to more complex congenital malformations with re-
spect to cytokine/MMP profiles would be an appropriate fu-
ture direction. Third, this study was performed in which the
nonspecific serine protease inhibitor aprotinin was adminis-
tered, which in and of itself can potentially alter inflammatory
pathways.16,24 Inasmuch as aprotinin is no longer available
for routine clinical use, then whether and to what degree
the cytokine/MMP profile may be altered in the early
postoperative period in the absence of this antifibrinolytic
therapy remains to be established. Nevertheless, a unique
cytokine profile emerged that appears to be Th2 polarized in
infants with VSD, with a dominant IL-6 response, a transient
IL-10 response, and an absent IL-4 response. The only cyto-
kine/MMP with an apparent relationship to crossclamp time
in this study was GM-CSF, which was suppressed by
long CPB times. For the MMPs, the neutrophil-associated1264 The Journal of Thoracic and Cardiovascular Surproteases MMP-8 and MMP-9 showed marked increases in
early post-CPB levels and later sustained elevations that
were inversely correlated with crossclamp times. MMP-3
showed a smaller post-CPB spike in expression and a steady
late increase that we attribute to wound healing activity. In
contrast, circulating levels of MMP-2 and MMP-7 were not
elevated above baseline at any time point afterCPB.Taken to-
gether, these findings suggest that the neutrophil-mediated
MMP response after VSD repair in infants is robust (MMP-
8 andMMP-9) but that early and late significant macrophage,
endothelial, and myocyte compartment responses are largely
suppressed or absent (MMP-2, MMP-7, anad MMP-12). The
mechanisms behind these unique patterns, the dissection of
beneficial from deleterious effects, and the benefits of thera-
peutic manipulation of the inflammatory state engendered
by CPB remain to be determined.
We are grateful to Nikole O’Quinn for her able assistance in the
preparation of this manuscript.References
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